Pancreatic cancer mystery deepens as researchers make unexpected discovery
FDA APPROVES ONCE-DAILY PILL FOR DEADLY CANCER AFTER PATIENTS' SURVIVAL RATES NEARLY DOUBLE Tumors from Black patients had fewer of the most common type of pancreatic cancer cells and more cells with a mix of different characteristics, the researchers found.
- A University of Cincinnati study found differences in pancreatic tumors that could help explain why that type of cancer affects some patients differently, potentially leading to more personalized treatments.
- Raymond Wadlow, a gastrointestinal medical oncologist at Inova Schar Cancer Institute in Virginia, said that using immunotherapy to help the immune system attack the disease has been particularly challenging in pancreatic cancer.
- "That's been very difficult to do in pancreatic cancer because the pancreatic tumor subverts the immune system so that it is fighting for it instead of for the host or the rest of the body," Wadlow, who was not involved in the study, told Fox News Digital.
Researchers examined 22 pancreatic tumors from patients of different racial backgrounds across the U.S., looking for differences in cancer cells and how the immune system responds to them.
- "That is potentially important both for understanding disparities in pancreatic cancer and, ultimately, for developing more individualized treatments." Pancreatic cancer can vary from one tumor to another, and even within the same tumor, Wadlow explained.
- Researchers found signs that some B cells may suppress the body’s response to cancer, although the significance of these differences is unclear.
- The team also needs to study pancreatic tissue from people without cancer to better understand when these differences develop.
- WHERE YOU LIVE COULD SHAPE YOUR RISK OF CANCER MORTALITY, STUDY SUGGESTS The findings highlight the importance of including patients from different backgrounds in cancer research, according to lead study author Nina Steele, Ph.D., an assistant professor in UC’s College of Medicine.
- CLICK HERE FOR MORE HEALTH STORIES Researchers have not established how the intermediate tumor cells affect survival or whether they respond differently to standard chemotherapy, Steele said.
How this summary was made: extractive summary — built from the sources' own reporting. It is drawn only from the reporting of the sources listed below — read the originals for full detail. How we summarize →